Borosil Scientific Limited — Credit Ratings, 11-12-2024: Credit Rating- New

Borosil Scientific Limited presents a robust financial outlook, showcasing significant growth in its consolidated financials. For H1FY25, the company reported a Total Operating Income (TOI) of ₹207 crore, reflecting a year-over-year increase of over 15% from ₹180 crore in H1FY24. This growth can largely be attributed to heightened demand for laboratory-related products driven by the pharmaceutical and medical research industries.

In terms of profitability, Borosil recorded a net profit of ₹14 crore for H1FY25 compared to ₹23 crore in FY24, an estimate that indicates an improvement in profit margins, with a PBILDT margin soaring to 12.22%, up from 8.46% in the previous year. These figures are indicative of a more favorable product mix and enhanced operational efficiencies across its business segments.

Operational costs saw fluctuations but remained manageable, reflecting a structured approach towards cost control in conjunction with rising revenue. Detailed assessments show operational costs impact stemming primarily from inflationary pressures in raw material pricing, particularly glass tubes, alongside a working capital cycle stabilization around 120 days.

The balance sheet remains strong, with overall gearing maintained at a conservative 0.06x, enhancing confidence in the company's financial leverage. As a result, liquidity appears robust, driven by strong cash flows and minimal reliance on external financing.

Strategically, Borosil is well-positioned to capitalize on promising growth prospects in various segments, particularly laboratory instruments and process equipment where they currently hold lower market shares. This expansion, coupled with critical investments in innovation and operational efficiency, could yield significant returns in the medium term.

Considering these insights, the outlook leans towards a buy strategy, given the favorable financial performance, enhanced operational margins, and promising market dynamics.